Security record · archived quarter
IHE
iShares U.S. Pharmaceuticals ETF · Financial Services · Asset Management
3Tracked holders
-2Δ holders
3.37MShares held
$237.66MReported value
+0New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 10.79K | $1.07M | n/a | −1 |
| Q2 2026 | 51 | +4 | 6.30M | $624.73M | +6 | −3 |
| Q1 2026 | 49 | +1 | 5.21M | $450.70M | +3 | −2 |
| Q4 2025 | 48 | +1 | 4.98M | $422.06M | +1 | n/a |
| Q3 2025 | 7 | +1 | 3.46M | $251.38M | +1 | n/a |
| Q2 2025 | 3 | 0 | 3.03M | $198.38M | n/a | n/a |
| Q1 2025 | 2 | -2 | 3.17M | $223.35M | n/a | −2 |
| Q4 2024 | 4 | +1 | 3.32M | $218.11M | +2 | −1 |
| Q3 2024 | 3 | -2 | 3.37M | $237.66M | n/a | −2 |
| Q2 2024 | 5 | n/a | 3.48M | $230.98M | n/a | n/a |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fisher Asset Management ✦ | 3.35M | -2.6% | $236.70M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Marshall Wace ✦ | 8.40K | +32.0% | $592,983 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 5.12K | -78.6% | $361,241 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $417,816 | was 0.0% |
| D. E. Shaw & Co. | $345,594 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 7.24M shares, $621.44M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API